Neuspera Medical today highlighted that the Centers for Medicare & Medicaid Services (CMS) has confirmed the assignment of the billing code for the Neuspera Sacral Neuromodulation System (SNM) to ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
94% of Test-Phase Responders Achieved Significant Symptom Relief with Zero Serious Device-Related Adverse Events New Data Suggests 30 Minutes of Daily iSNM Therapy Provides UUI Symptom Relief ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
A pioneering study has introduced a novel approach to enhance the treatment of large sacral chordomas using carbon ion therapy. The study focuses on optimizing dose-averaged linear energy transfer ...
Reimbursement Parity Advances Patient Access and Will Help More Patients Avoid the Pain, Complications, and Repeat Surgeries Common in the $1 Billion Legacy Sacral Neuromodulation (SNM) Market Served ...
SAN JOSE, Calif., July 8, 2026 /PRNewswire/ -- Neuspera Medical today highlighted that the Centers for Medicare & Medicaid Services (CMS) has confirmed the assignment of the billing code for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results